The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5
2017
Introduction
Lenalidomide is an active agent that was approved for use in the EU in 2015 as a first-line therapy for previously untreated, non-transplant eligible multiple myeloma patients. Our objective was to assess the cost impact of lenalidomide when selected as a first-line treatment for transplant-ineligible patients in France, Germany, Italy, Spain, and the United Kingdom (EU5).
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
15
References
3
Citations
NaN
KQI